Genes differentially expressed in prostate cancer
暂无分享,去创建一个
G Bartsch | H. Klocker | G. Bartsch | P. Hååg | J. Bektic | I E Eder | H Klocker | J Bektic | P Haag | I. Eder
[1] A. Schned,et al. Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-Fc&ggr;RI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu , 2001, Journal of immunotherapy.
[2] K. Meehan,et al. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer , 2002, The Prostate.
[3] K. Porkka,et al. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array , 2001, The Journal of pathology.
[4] H. Klocker,et al. Prostate cancer screening in Tyrol, Austria: experience and results. , 2000, European urology.
[5] J. Brooks,et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[6] Arul M Chinnaiyan,et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.
[7] J. Epstein,et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.
[8] G. Hortobagyi,et al. Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.
[9] Michael J. Wilson,et al. Expression of matrix metalloproteinase‐2 and ‐9 and their inhibitors, tissue inhibitor of metalloproteinase‐1 and ‐2, in primary cultures of human prostatic stromal and epithelial cells * † , 2002, Journal of cellular physiology.
[10] D. Mercola,et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo , 2003, Oncogene.
[11] Biaoyang Lin,et al. The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] T. Stamey,et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.
[13] A. Menssen,et al. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. , 2002, Cancer research.
[14] M. Gleave,et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] H. Klocker,et al. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells , 2003, Molecular carcinogenesis.
[16] L. Hood,et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. , 1998, Cancer research.
[17] L. Klotz,et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.
[18] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[19] W. Powell,et al. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene. , 1999, The American journal of pathology.
[20] J. Schiller. New directions for ZD1839 in the treatment of solid tumors. , 2003, Seminars in oncology.
[21] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[22] Spyro Mousses,et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.
[23] L. Kiemeney,et al. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .
[24] H. Bonkhoff,et al. Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma , 2003, The Prostate.
[25] H. Miyake,et al. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] T. Roskams,et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.
[27] J. Moul,et al. Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes , 2001, International journal of cancer.
[28] A. Zietman,et al. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. , 2000, Urology.
[29] A. Wakeling,et al. Growth factors and their receptors: new targets for prostate cancer therapy. , 2001, Urology.
[30] L. Bubendorf,et al. Expression of NKX3.1 in normal and malignant tissues , 2003, The Prostate.
[31] B. Gumbiner,et al. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin , 2003, The Journal of cell biology.
[32] A. Belldegrun,et al. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. , 2003, Cancer research.
[33] M. Jordá,et al. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. , 2002, The Journal of urology.
[34] J. Welsh,et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.
[35] S. Egawa,et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. , 2002, Anticancer research.
[36] J. Swinnen,et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. , 2003, Biochemical and biophysical research communications.
[37] J. Richie,et al. Expression of cell cycle-regulated proteins in prostate cancer. , 1996, Cancer research.
[38] E. Riboli,et al. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. , 2001, The Journal of clinical endocrinology and metabolism.
[39] K. Pienta,et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. , 2001, Human pathology.
[40] M. Gleave,et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. , 2001, Urology.
[41] I. Mellinghoff,et al. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. , 2002, Cancer research.
[42] M. Gleave,et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. , 2003, Cancer research.
[43] H. Frierson,et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. , 1997, The Journal of urology.
[44] E Mahlamäki,et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.
[45] M. Bittner,et al. Expression profiling using cDNA microarrays , 1999, Nature Genetics.
[46] H. Miyake,et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.
[47] H. Kanetake,et al. Serum insulin‐like growth factor binding protein‐3/prostate‐specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer , 2003, The Prostate.
[48] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[49] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[50] H. Klocker,et al. Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic , 2001, European Urology.
[51] E. Small,et al. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. , 2001, Seminars in oncology.
[52] R. Cheng,et al. Age-Associated Changes in Histology and Gene-Expression Profile in the Rat Ventral Prostate , 2003, Laboratory Investigation.
[53] R. Cardiff,et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[54] Zhou Wang,et al. Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.